Occudo Quantitative Strategies LP Cel Sci Corp Transaction History

Occudo Quantitative Strategies LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.99 - $3.52 $27,670 - $48,945	-13,905 Reduced 55.54%	11,131 $26,000
Q3 2022 Nov 14, 2022	SELL	$3.09 - $5.23 $104,386 - $176,679	-33,782 Reduced 57.43%	25,036 $77,000
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $107,774 - $208,447	-41,773 Reduced 41.53%	58,818 $265,000
Q1 2022 May 16, 2022	BUY	$3.93 - $7.7 $395,322 - $774,550	100,591 New	100,591 $395,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.